Kuehn Law, PLLC, is investigating potential breaches of fiduciary duty by certain officers and directors of Medpace Holdings, Inc. (NASDAQ: MEDP), alleging that the company misled investors regarding critical business metrics. According to a federal securities lawsuit, Medpace Holdings misrepresented or failed to disclose material information concerning its backlog cancellation rates, business conditions, and ability to maintain its projected 1.15 book-to-bill ratio. These disclosures allegedly provided investors with overly optimistic growth expectations, causing them to purchase common stock at artificially inflated prices.

Key Allegations and Investigation Scope

The investigation centers on claims that Medpace Holdings' leadership failed to provide accurate transparency about the sustainability of its growth projections. Specifically, the lawsuit highlights discrepancies in the reported backlog cancellation rates and the feasibility of maintaining the stated 1.15 book-to-bill ratio. Kuehn Law asserts that these omissions and misrepresentations materially impacted the stock's valuation, leading to financial harm for shareholders who relied on the company's public statements.

Shareholder Action Required

Investors who currently own MEDP shares and purchased them prior to April 22, 2025, are urged to contact Kuehn Law immediately. Sophia Anne Silayan can be reached via email at sophiaanne@kuehn.law or by phone at (833) 672-0814. The firm emphasizes that there may be limited time to enforce legal rights, making prompt action essential for affected shareholders. Kuehn Law pays all case costs and does not charge its investor clients, removing financial barriers to participation in the potential litigation.

Why Participation Matters

As a shareholder, your involvement contributes to the integrity and fairness of the financial markets. By engaging with the investigation, investors help ensure that corporate leadership remains accountable for accurate financial reporting. Your investment, voice, and future are directly tied to the outcome of these proceedings.

For additional information on shareholder derivative litigation, visit the Kuehn Law website. Attorney advertising: Prior results do not guarantee similar outcomes.

Medpace Holdings, Inc. reported second quarter 2026 earnings per share of $4.25, beating the analyst consensus estimate of $3.97 by 7.05%. This represents a 37.1% increase from earnings of $3.10 per share in the same period last year. Revenue rose 17.2% to $707.3 million, surpassing the analyst consensus estimate of $687.6 million. Net income increased 34.4% to $121.4 million, compared to $90.3 million in the prior year. EBITDA grew 17.6% to $153.4 million, resulting in an EBITDA margin of 21.7%.

Financial Results

Revenue growth was driven by strong operational performance, with total direct costs increasing to $505.7 million from $423.3 million. Selling, general and administrative expenses were $48.1 million, compared to $46.7 million in the prior year. Net income margin improved to 17.2% from 15.0% in the second quarter of 2025. Net new business awards totaled $795.7 million, a 28.2% increase from the prior-year period, with a net book-to-bill ratio of 1.13x. Backlog as of June 30, 2026, increased 4.9% to $3,014.2 million.

For the six months ended June 30, 2026, revenue was $1,413.9 million, an increase of 21.7% on a reported basis. Year-to-date net income was $245.2 million, or $8.53 per diluted share, compared to $204.9 million, or $6.79 per diluted share, in the prior year. Year-to-date EBITDA was $302.8 million, a 21.5% increase on a reported basis.

Balance Sheet and Liquidity

Cash and cash equivalents were $502.7 million at June 30, 2026. The company generated $162.0 million in cash flow from operating activities during the quarter. During the second quarter of 2026, Medpace repurchased 705,616 shares for a total of $294.7 million. As of June 30, 2026, the company had $527.0 million remaining under its authorized share repurchase program.

2026 Financial Guidance

Medpace forecasts 2026 revenue in the range of $2.805 billion to $2.885 billion, representing growth of 10.9% to 14.0% over 2025 revenue of $2.530 billion. GAAP net income for full year 2026 is forecasted in the range of $494.0 million to $514.0 million. Full year 2026 EBITDA is expected in the range of $618.0 million to $642.0 million. Diluted earnings per share (GAAP) is forecasted in the range of $17.25 to $17.95.